ResearchBIORXIVMay 6
Preprint: Variation in Tolvaptan Prescribing for Autosomal Dominant Polycystic Kidney Disease in the United Kingdom and Its Impact on Quality of Life and Costs
A new study looked at how often doctors in the UK prescribe tolvaptan, a medicine that slows kidney disease in patients with ADPKD (a genetic condition where cysts grow in the kidneys). The researchers found that some patients who should get this medicine don't receive it, while others who aren't eligible do get it. This variation in prescribing patterns may affect how well patients do and how much the healthcare system spends.
WHY IT MATTERSIf you have ADPKD in the UK, this research could help explain why access to tolvaptan—the only disease-slowing treatment available—varies depending on which kidney center treats you.